Risperidone-associated Transient Diabetic Ketoacidosis and Diabetes Mellitus Type 1 in a Patient Treated with Valproate and Lithium

B. Mithat; T. Alpaslan; C. Bulent; T. Cengiz

doi:10.1055/s-2005-837815

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2005; 38(2): 105-106
DOI: 10.1055/s-2005-837815

Letter

Risperidone-associated Transient Diabetic Ketoacidosis and Diabetes Mellitus Type 1 in a Patient Treated with Valproate and Lithium

A Case ReportB. Mithat¹ , T. Alpaslan² , C. Bulent³ , T. Cengiz⁴

¹Associated Professor, Departments of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
²Assistant Professor, Departments of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
³Research Fellow, Internal Medicine, University of Dicle, School of Medicine, Diyarbakir, Turkey
⁴Assistant Professor, Biochemistry, University of Dicle, School of Medicine, Diyarbakir, Turkey

Abstract

A 37-year-old man treated with valproate and lithium for bipolar affective disorder since 1999 and with risperidone since March 2003 was admitted to our clinic due to metabolic acidosis. Serum glucose was 647 mg/dL and urine ketones were positive. The patient was accepted as diabetic ketoacidosis (DKA). Risperidone, valproate, and lithium were immediately stopped, and the patient was treated with insulin and IV fluid replacement. Serum insulin and C-peptide levels were too low, and islet cell antibody and anti-GAD antibody were positive. We accepted him as type 1 diabetes mellitus (DM type 1). After the intensive treatment of diabetes, insulin requirements decreased gradually and diabetes mellitus disappeared completely within three months. Conclusion: Risperidone may lead to transient DM type 1 and DKA.

Volltext

Referenzen

References

1 Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom. 2002; 71 (5) 244-254
2 Baptista T, Kin N M, Beaulieu S, de Baptista E A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002; 35 (6) 205-19
3 Cohen D. Atypical antipsychotics and new onset diabetes mellitus - an overview of the literature. Pharmacopsychiatry. 2004; 37 (6) 1-11
4 Croarkin P E, Jacobs K M, Bain B K. Diabetic ketoacidosis associated with risperidone treatment?. Psychosomatics. 2000; 41 369-370
5 Gitlin M. Lithium and the kidney: an updated review. Drug Saf.. 1999; 20 (3) 231-43
6 Haupt D W, Newcomer J W. Risperidone-associated diabetic ketoacidosis. Psychosomatics. 2001; 42 (3) 279-80
7 Jin H, Meyer J M, Jeste D V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002; 14 (1) 59-64

Mithat Bahceci, MD

Dicle Universiti Tip Fakultesi

Endokrinoloji BD

21280 Diyarbakir-Turkey

Telefon: +90 412 2488001

Fax: +90 412 2488520

eMail: mbahceci@dicle.edu.tr